Aprea Therapeutics (APRE) Stock Price, News & Analysis

Company Overview

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS. In addition to its lead program, Aprea maintains a pipeline of early‐stage candidates and explores combination regimens intended to enhance response rates and overcome resistance mechanisms associated with TP53 dysfunction.

Aprea conducts global clinical development activities, collaborating with academic centers and biopharmaceutical partners in North America and Europe. These partnerships support Aprea’s efforts to accelerate trial enrollment, broaden access to investigational therapies and facilitate regulatory interactions across multiple jurisdictions.

Founded in 2013 and headquartered in San Francisco, California, Aprea is led by a management team with extensive experience in oncology drug development. The company’s scientific leadership combines expertise in molecular biology, translational research and clinical operations to advance its precision oncology approach for patients with high‐unmet‐need cancers.

Key Stats

• Today's Range: $0.78 to $0.85
• 50-Day Range: $0.60 to $0.98
• 52-Week Range: $0.55 to $1.69
• Volume: 375,323 shs
• Average Volume: 999,702 shs
• Market Capitalization: $10.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.07
• Consensus Rating: Hold

Aprea Therapeutics Stock Analysis - MarketRank™

Aprea Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 267th out of 917 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Aprea Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Aprea Therapeutics has a consensus price target of $3.07, representing about 283.3% upside from its current price of $0.80.

Amount of Analyst Coverage

Aprea Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Aprea Therapeutics are expected to decrease in the coming year, from ($0.32) to ($0.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aprea Therapeutics is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aprea Therapeutics is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aprea Therapeutics has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.05% of the float of Aprea Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aprea Therapeutics has a short interest ratio ("days to cover") of 0.12, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aprea Therapeutics has recently decreased by 86.64%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aprea Therapeutics does not currently pay a dividend.

Dividend Growth

Aprea Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.45

News Sentiment

Aprea Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.98 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Aprea Therapeutics this week, compared to 3 articles on an average week.

Search Interest

1 people have searched for APRE on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Aprea Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aprea Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.49% of the stock of Aprea Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

34.19% of the stock of Aprea Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 8/31/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:APRE
• CIK: 1781983
• Web: www.aprea.com
• Phone: 617-463-9385
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Aprea Therapeutics: $3.07
• High Price Target: $5.00
• Low Price Target: $1.20
• Potential Upside/Downside: +281.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.60 million
• Net Margins: -4,405.59%
• Pretax Margin: -246,140.02%
• Return on Equity: -47.60%
• Return on Assets: -40.97%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.56
• Quick Ratio: 13.56

Sales & Book Value

• Annual Sales: $290 thousand
• Price / Sales: 34.87
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.52 per share
• Price / Book: 0.53

Miscellaneous

• Outstanding Shares: 12,590,000
• Free Float: 11,270,000
• Market Cap: $10.11 million
• Optionable: No Data
• Beta: 1.52